Long Term Safety Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study

NCT02002936 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

1

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelodysplastic Syndrome

Interventions

DRUG: SyB C-1101

Sponsor

SymBio Pharmaceuticals